✕Medical Affairs Document Co-PilotStep 3 Previous
Matching Cockpit
⌖Selected Section
▤
▦Brief Section Summary
Economic evaluations aim to inform decisions and require a comprehensive account of the decision problem. Specifying a decision problem involves identifying the perspective, interventions, and measures for comparison. Costs and outcomes depend on the decision-maker's perspective, and multiple perspectives may be needed for multiple decision-makers. Interventions should be clearly defined, considering all relevant options and best supportive care when necessary. The decision problem should identify costs to be included, consistent with the stated perspective, and specify the time horizon for both costs and outcomes. Subgroup variations should be considered, and consultation with clinicians, target population members, and decision-makers is essential for a thorough understanding of all available evidence.
⑂ Linked Dossier Pages
9.0
Confirmed · No
Explanation ·
The text is highly relevant to the health technology assessment filing as it provides detailed unit costs and resource use estimates, which are essential components of the economic evaluation section of such filings. The information is sourced from credible references and includes a scenario analysis, which adds to the robustness of the data. It is not a perfect score because there might be additional context or data outside of this excerpt that could be pertinent to the filing.
Score · 9
Page Number · 123
Chunk Id · ri.mio.main.media-item.32daedf7-4188-407b-b353-7a33ee738aa6_123
9.0
Confirmed · No
Explanation ·
The text is highly relevant to Health Technology Assessment filings as it covers key components such as treatment comparisons, modelling techniques, health states, time horizons, discount rates, and perspectives, which are all essential for HTA submissions. It specifically mentions NICE HTA submissions and their requirements, indicating that it aligns well with HTA standards. The score is not a perfect 10 as there may be specific template instructions not addressed in the text, and without those instructions, the assessment cannot be definitive.
Score · 9
Page Number · 86
Chunk Id · ri.mio.main.media-item.7e9afa5b-64f3-4c1a-80df-1f9c797d1680_86
7.0
Confirmed · No
Explanation ·
The excerpt describes the decision problem and comparator selection for the Canadian setting, matching the template section, though it references the UK perspective in places.
Score · 7
Page Number · 41
Chunk Id · ri.mio.main.media-item.1c2b3e4f-5a6b-4c7d-8e9f-0a1b2c3d4e5f_41
4.0
Confirmed · No
Explanation ·
The introduction gives background on the disease area; it is only tangentially relevant to the decision problem section.
Score · 4
Page Number · 12
Chunk Id · ri.mio.main.media-item.9f8e7d6c-5b4a-4392-8170-6f5e4d3c2b1a_12
Source Document Viewer9 Out of 10
123/ 417
B.3.5.2 Health-state unit costs and resource use

Unit costs for supportive care are listed in Table 49 and were sourced from NHS reference costs 2018/2019 and PSSRU 2019 (143, 144).

Resource use estimates in the base case were derived from a questionnaire of 6 UK clinicians currently treating patients with HCC. This was conducted in early 2020 in preparation for this submission, in order to provide current estimates since the literature estimates were based on evidence collected over 10 years ago. Values used in the base case are provided in Table 50.

A scenario analysis has been included utilising the resource use estimates from the lenvatinib NICE submission TA551 (Table 51) (42), whereby resource use estimates were obtained from the original sorafenib submission (38). As TA551 used estimates from the sorafenib submission, which was partly carried out over 10 years ago in 2009 and partly updated in 2016, the values in Table 50 were deemed the most recent and clinically relevant.

Table 49: Resource use costs
Resource requiredUnit CostReference
Physician visitsOncologist£194.17NHS reference costs 2018/19. WF01A Consultant-led, Non-Admitted Face-to-Face Attendance, Follow-up (medical oncology)
Hepatologist£194.79NHS reference costs 2018/19. WF01A Consultant-led, Non-Admitted Face-to-Face Attendance, Follow-up (hepatology)
Gastroenterologist£137.88NHS reference costs 2018/19. WF01A Consultant-led, Non-Admitted Face-to-Face Attendance, Follow-up (gastroenterology)
Macmillan nurse£36.65PSSRU, Unit Costs of Health and Social Care 2018/19. Nurse (GP practice). Cost per hour, including qualifications
Radiologist£151.85NHS reference costs 2018/19. WF01A Consultant-led, Non-Admitted Face-to-Face Attendance, Follow-up (interventional radiology)
Laboratory testsAFP Test£23.71NHS reference costs 2018/19. Average of DAPS01 and DAPS02 (cytology, and histopathology and histology)
Section Draft Viewer